ArticleNeurology2025
Cortical Gray Matter Proteins Associated With Cerebral Amyloid Angiopathy in Community-Dwelling Older Adults: An Autopsy Study.
Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How does type 2 diabetes modify the risk of Alzheimer's disease?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesCerebral amyloid angiopathy (CAA) is the accumulation of β-amyloid (Aβ) in the walls of small vessels in the leptomeninges and cortex and is a risk factor of intracerebral hemorrhage and dementia, but its underlying mechanism is unknown. We examined cortical proteins in relation to CAA to elucidate the molecular mechanisms underlying CAA.
methodsData were collected from participants of 5 community-based cohorts of older adults. Participants were recruited from personal dwellings or retirement centers, were without known dementia at enrollment, and signed an Anatomic Gift Act for brain donation. At death, autopsy was performed and cortical proteins were quantified from the dorsolateral prefrontal cortex using mass spectrometry-based proteomic analysis, and pathologic indices of brain pathologies including CAA and Alzheimer disease (AD) were assessed during neuropathologic evaluations. Targeted mass spectrometry-based proteomic analysis was performed for the quantification of total Aβ protein and Aβ38 peptide. Ordinal logistic regression models were used to test the association between the proteins and CAA.
resultsA total of 887 participants were included, with a mean age at death of 89.0 (SD = 6.8) years, and 67.2% (n = 596) were women. Eighty proteins were related to CAA, of which 12 remained associated with CAA after controlling for AD pathology. However, only 4 proteins remained associated with CAA when all 12 proteins were examined in a single model: secreted modular calcium-binding protein 1 (SMOC1), secreted frizzled-related protein 1 (SFRP1), APOE, and APOE4. Examining the 4 proteins together with the 3 Aβ measures (Aβ load, total Aβ protein, and Aβ38 peptide) in a factor analysis and a structure equation model suggested 2 factors and paths: a factor including Aβ38, SFRP1, and APOE protein, which had the larger effect size in relation to CAA (standardized estimate = 0.459, SE = 0.050, DISCUSSION: This study suggests 2 molecular pathways underlying CAA, with a larger effect size for the pathway including SFRP1 and APOE protein and C-terminally truncated Aβ before position 40. However, the study is an observational cross-sectional study that limits causal inference from the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.